6505--Amiodarone HCL Tablets

The Department of Veterans Affairs National Acquisition Center is soliciting offers for Amiodarone Hydrochloride tablets through solicitation 36E79726R0014. This procurement encompasses three line items: 100 mg tablets in 30-count unit-of-use bottles (54,951 estimated annual units), 200 mg tablets in 60-count unit-of-use bottles (108,834 estimated annual units), and 200 mg tablets in 500-count bottles (18,775 estimated annual units). Offerors must meet all FDA cGMP standards, comply with Drug Supply Chain Security Act requirements, obtain NABP trading partner registration, and establish business-to-business agreements with Pharmaceutical Prime Vendor contractors serving the VA, Department of Defense, Federal Health Care Centers, State Veteran Homes, Indian Health Service, and Bureau of Prisons. The evaluation criterion is lowest price technically acceptable, with award made to the responsible offeror meeting all solicitation requirements. The original offer deadline of March 31, 2026, was extended twice—first to April 7, 2026, and ultimately to April 13, 2026, at 2:30 PM Central Time, with offerors required to acknowledge receipt of all amendments prior to submission.

This solicitation carries no set-aside designation and does not identify any current contractors or incumbents. The contract structure includes a one-year base ordering period plus four one-year option periods, with an implementation period not to exceed 60 calendar days following award. Offerors must submit pricing for all three line items across the base year and all four option years to be considered for award, with prices including a mandatory 0.5% Cost Recovery Fee and not exceeding two decimal places. Non-small business concerns must submit an approved subcontracting plan with minimum goals for service-disabled veteran-owned and veteran-owned small business participation. While specific budget ranges are not disclosed in the solicitation documents, the estimated combined annual usage across all three line items and all eligible federal facilities indicates substantial volume requirements typical of multi-agency pharmaceutical supply contracts.